한빛사논문
Jeongsoo Hur 1, Hyelee Kim 1,2, Uijin Kim 3, Gi-Beom Kim 1,4, Jinho Kim 5, Byeongju Joo 4, Duck Cho 5,6, Dong-Sung Lee 3, Aram J Chung 1,2,4,7
1Department of Bioengineering, Korea University, Seoul 02841, Republic of Korea.
2Interdisciplinary Program in Precision Public Health (PPH), Korea University, Seoul 02841, Republic of Korea.
3Department of Life Sciences, University of Seoul, Seoul 02504, Republic of Korea.
4MxT Biotech, Seoul 04785, Republic of Korea.
5Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul 06355, Republic of Korea.
6Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 03063, Republic of Korea.
7School of Biomedical Engineering, Korea University, Seoul 02841, Republic of Korea.
Corresponding Authors : Dong-Sung Lee, Aram J. Chung
Abstract
Effective tumor regression has been observed with chimeric antigen receptor (CAR) T cells; however, the development of an affordable, safe, and effective CAR-T cell treatment remains a challenge. One of the major obstacles is that the suboptimal genetic modification of T cells reduces their yield and antitumor activity, necessitating the development of a next-generation T cell engineering approach. In this study, we developed a nonviral T cell nanoengineering system that allows highly efficient delivery of diverse functional nanomaterials into primary human T cells in a genetically stable and scalable manner. Our platform leverages the unique cell deformation and restoration process induced by the intrinsic inertial flow in a microchannel to create nanopores in the cellular membrane for macromolecule internalization, leading to effective transfection with high scalability and viability. The proposed approach demonstrates considerable potential as a practical alternative technique for improving the current CAR-T cell manufacturing process.
논문정보
관련 링크
연구자 키워드
관련분야 연구자보기
관련분야 논문보기
해당논문 저자보기